Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer

被引:1063
作者
Kelsen, DP
Ginsberg, R
Pajak, TF
Sheahan, DG
Gunderson, L
Mortimer, J
Estes, N
Haller, DG
Ajani, J
Kocha, W
Minsky, BD
Roth, JA
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[2] Radiat Therapy Oncol Grp, Stat Off, Philadelphia, PA USA
[3] Univ Pittsburgh, Pittsburgh, PA USA
[4] Mayo Clin, Rochester, MN USA
[5] Washington Univ, St Louis, MO USA
[6] Univ Kansas, Lawrence, KS 66045 USA
[7] Univ Penn, Philadelphia, PA 19104 USA
[8] MD Anderson Canc Ctr, Houston, TX USA
[9] Univ Western Ontario, London, ON, Canada
关键词
D O I
10.1056/NEJM199812313392704
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Background We performed a multi-institutional randomized trial comparing preoperative chemotherapy followed by surgery with surgery alone for patients with local and operable esophageal cancer. Methods Preoperative chemotherapy for patients randomly assigned to the chemotherapy group included three cycles of cisplatin and fluorouracil. Surgery was performed two to four weeks after the completion of the third cycle; patients also received two additional cycles of chemotherapy after the operation. Patients randomly assigned to the immediate-surgery group underwent the same surgical procedure. The main end point was overall survival. Results Of the 440 eligible patients with adequate data, 213 were assigned to receive preoperative chemotherapy and 227 to undergo immediate surgery. After a median possible study time of 55.4 months, there were no significant differences between the two groups in median survival: 14.9 months for the patients who received preoperative chemotherapy and 16.1 months for those who underwent immediate surgery (P=0.53). At one year, the survival rate was 59 percent for those who received chemotherapy and 60 percent for those who had surgery alone; at two years, survival was 35 percent and 37 percent, respectively. The toxic effects of chemotherapy were tolerable, and the addition of chemotherapy did not appear to increase the morbidity or mortality associated with surgery. There were no differences in survival between patients with squamous-cell carcinoma and those with adenocarcinoma. Weight loss was a significant predictor of poor outcome (P=0.03). With the addition of chemotherapy, there was no change in the rate of recurrence at locoregional or distant sites. Conclusions Preoperative chemotherapy with a combination of cisplatin and fluorouracil did not improve overall survival among patients with epidermoid cancer or adenocarcinoma of the esophagus. (N Engl J Med 1998;339:1979-84.) (C) 1998, Massachusetts Medical Society.
引用
收藏
页码:1979 / 1984
页数:6
相关论文
共 23 条
[1]
ACTIVITY OF TAXOL IN PATIENTS WITH SQUAMOUS-CELL CARCINOMA AND ADENOCARCINOMA OF THE ESOPHAGUS [J].
AJANI, JA ;
ILSON, DH ;
DAUGHERTY, K ;
PAZDUR, R ;
LYNCH, PM ;
KELSEN, DP .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (14) :1086-1091
[2]
AlSarraf, 1997, J CLIN ONCOL, V15, P866
[3]
Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: An intergroup study [J].
AlSarraf, M ;
Martz, K ;
Herskovic, A ;
Leichman, L ;
Brindle, JS ;
Vaitkevicius, VK ;
Cooper, J ;
Byhardt, R ;
Davis, L ;
Emami, B .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) :277-284
[4]
RISING INCIDENCE OF ADENOCARCINOMA OF THE ESOPHAGUS AND GASTRIC CARDIA [J].
BLOT, WJ ;
DEVESA, SS ;
KNELLER, RW ;
FRAUMENI, JF .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (10) :1287-1289
[5]
Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus [J].
Bosset, JF ;
Gignoux, M ;
Triboulet, JP ;
Tiret, E ;
Mantion, G ;
Elias, D ;
Lozach, P ;
Ollier, JC ;
Pavy, JJ ;
Mercier, M ;
Sahmoud, T .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (03) :161-167
[6]
COX DR, 1972, J R STAT SOC B, V34, P187
[7]
A CLASS OF K-SAMPLE TESTS FOR COMPARING THE CUMULATIVE INCIDENCE OF A COMPETING RISK [J].
GRAY, RJ .
ANNALS OF STATISTICS, 1988, 16 (03) :1141-1154
[8]
COMBINED CHEMOTHERAPY AND RADIOTHERAPY COMPARED WITH RADIOTHERAPY ALONE IN PATIENTS WITH CANCER OF THE ESOPHAGUS [J].
HERSKOVIC, A ;
MARTZ, K ;
ALSARRAF, M ;
LEICHMAN, L ;
BRINDLE, J ;
VAITKEVICIUS, V ;
COOPER, J ;
BYHARDT, R ;
DAVIS, L ;
EMAMI, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (24) :1593-1598
[9]
ILSON DH, 1994, SEMIN ONCOL, V21, P493
[10]
Kalbfleisch JD., 2011, The statistical analysis of failure time data